Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNF alpha Therapy by Valk, M.E. van der et al.
Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. 
For permissions, please email: journals.permissions@oup.com
1016
Original Article
Comparison of Costs and Quality of Life in 
Ulcerative Colitis Patients with an Ileal Pouch–Anal 
Anastomosis, Ileostomy and Anti-TNFα Therapy
Mirthe E. van der Valk1, Marie-Josée J. Mangen2, Mirjam Severs1,  
Mike van der Have1, Gerard Dijkstra3, Ad A. van Bodegraven4,8,  
Herma H. Fidder1, Dirk J. de Jong5, Marieke Pierik6,  
C. Janneke van der Woude7, Mariëlle J.L. Romberg-Camps8,  
Cees H.M. Clemens9, Jeroen M. Jansen10, Paul C. van de Meeberg11 , 
Nofel Mahmmod12, Andrea E. van der Meulen-de Jong13,  
Cyriel Y. Ponsioen14, Clemens Bolwerk15, J. Reinoud Vermeijden16,  
Peter D. Siersema1, Max Leenders1, Bas Oldenburg1, on behalf of the 
COIN study group and the Dutch Initiative on Crohn and Colitis
1Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht, The Netherlands 
2Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, The 
Netherlands 3Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, 
 The Netherlands 4Department of Gastroenterology and Hepatology, VU University Medical Centre, Amsterdam, 
The Netherlands 5Department of Gastroenterology and Hepatology, Radboud University Nijmegen Medical Centre, 
Nijmegen, The Netherlands 6Department of Gastroenterology and Hepatology, Maastricht University Medical  
Centre, Maastricht, The Netherlands 7Department of Gastroenterology and Hepatology, Erasmus University 
Medical Centre, Rotterdam, The Netherlands 8Department of Gastroenterology and Hepatology, Orbis Medical 
Centre, Sittard, The Netherlands 9Department of Gastroenterology and Hepatology, Diaconessenhuis, Leiden, The 
Netherlands 10Department of Gastroenterology and Hepatology, Onze Lieve Vrouwe Gasthuis, Amsterdam, The 
Netherlands 11Department of Gastroenterology and Hepatology, Slingeland Hospital, Doetinchem, The Netherlands 
12Department of Gastroenterology and Hepatology, Antonius Hospital, Nieuwegein, The Netherlands 13Department 
of Gastroenterology and Hepatology, Leiden University Medical Centre, Leiden, The Netherlands. 14Department 
of Gastroenterology and Hepatology, Academic Medical Centre Amsterdam, Amsterdam, The Netherlands 
15Department of Gastroenterology and Hepatology, Reinier de Graaf Groep, Delft, The Netherlands 16Department of 
Gastroenterology and Hepatology, Meander Medical Centre, Amersfoort, The Netherlands
Corresponding author: Bas Oldenburg, MD, PhD, PO Box 85500, 3508 GA Utrecht, The Netherlands. Tel: 0031 887557325; fax: 
0031 887555533; Email: boldenbu@umcutrecht.nl
Abstract
Background and Aims: More data are warranted on the economic impact of different treatment 
strategies in ulcerative colitis (UC) patients. We compared the costs and quality of life of UC patients 
with a pouch reconstruction, an ileostomy or anti-tumour necrosis factor α (TNFα) therapy.
Methods: UC patients filled out 3-monthly questionnaires for 2  years. Differences in 3-monthly 
healthcare costs, productivity costs and patient costs were tested using mixed model analysis. Quality 
of life was assessed employing the ) and the inflammatory bowel disease questionnaire (IBDQ).
Results: Out of 915 UC patients, 81 (9%) had a pouch and 48 (5%) an ileostomy, and 34 (4%) 
were on anti-TNFα therapy. Anti-TNFα-treated patients reported high UC related-healthcare costs 
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per 3  months (€5350). Medication use accounted for 92% of healthcare costs. UC-attributable 
healthcare costs were 3-fold higher in ileostomy patients compared with pouch patients (€1581 
versus €407; p < 0.01). Main cost drivers in ileostomy patients were healthcare costs and ileostomy 
supplies (2 and 23% of healthcare costs, respectively). In pouch patients, the main cost driver was 
hospitalization, accounting for 50% of healthcare costs. Productivity loss did not differ between 
pouch and ileostomy patients (€483 versus €377; p < 0.23), but was significantly higher in anti-TNFα-
treated patients (€1085). No difference was found in IBDQ scores, but pouch patients were found to 
have higher quality-adjusted life years than ileostomy patients and anti-TNFα-treated patients (0.90 
[interquartile range 0.78–1.00] versus 0.84 [0.78–1.00] and 0.84 [0.69–1.00], respectively; p < 0.01).
Conclusion: Patients receiving anti-TNFα therapy reported the highest healthcare cost, in which 
medication use was the major cost driver. Ileostomy patients were three times more expensive 
than pouch patients due to frequent hospitalization and ileostomy supplies.
1. Introduction
The management of ulcerative colitis (UC) has changed dramatically 
over the past 10 years, with an increasing role of anti-TNFα drugs in 
patients failing conservative therapy.1 However, anti-TNFα therapy 
is expensive and accounts for one-third of UC-related healthcare 
costs.2
A restorative proctocolectomy with construction of an ileoanal 
pouch–anal anastomosis (pouch) is an alternative treatment option. 
Pouch surgery preserves body image and restores the conservative 
route of defaecation.3 However, the construction of a pouch is a 
difficult surgical procedure and complications are common, such 
as the occurrence of pouchitis,4–7 and decreased fecundity in young 
women.8 Recently, a significant reduction of complications after 
pouch surgery has been reported and overall success rates of 96.3% 
after 5 years, 92.4% after 10 years and 92.1% after 20 years have 
been described.9
In the emergency setting or in case of contraindications for pouch 
surgery, such as an impaired sphincter function, significant comor-
bidities or an unclear diagnosis (inflammatory bowel disease [IBD]-
unclassified), the surgical procedure of choice is a colectomy with an 
end-ileostomy and a closed rectal stump.3 A number of studies have 
shown that this procedure is safe in the emergency setting with a 
post-operative complication rate varying from 23 to 33%.10,11 In the 
absence of contraindications, pouch reconstruction may be consid-
ered over time in these cases as well.
To date, no studies comparing long-term outcomes of medi-
cally versus surgically treated patients have been published. In 
the light of the escalating costs of healthcare, more data on the 
economic impact of different treatment strategies are warranted in 
UC patients failing conservative treatment. We aimed to study the 
costs and quality of life of UC patients with a pouch, an ileostomy 




In 2010 we initiated the Costs Of Inflammatory Bowel Disease 
(COIN) study in The Netherlands in order to evaluate the total 
costs of IBD. We have published the cohort organization and results 
on the internal validity of our cohort in detail elsewhere.2,12 In sum-
mary, between October 2010 and October 2011 we invited by letter 
all identified IBD patients aged 18 years or older from seven univer-
sity hospitals and seven general hospitals to participate in the COIN 
study. Identification was based on diagnosis–treatment combinations. 
We developed a secure web-based questionnaire to obtain longitudi-
nal data on costs and quality of life. All patients were followed up for 
2 years at 3-month intervals. The web-based questionnaires contained 
questions on demographic and clinical characteristics, as well as costs 
and quality of life. Demographic characteristics included sex, age, age 
at diagnosis, education level, work status and smoking status. Clinical 
characteristics included subtype of IBD, disease duration and localiza-
tion, penetrating disease course and self-reported disease activity.
2.2. Patient population
For the current analysis we compared three groups of UC patients. 
The first group consisted of UC patients who had had pouch sur-
gery before the start of the study. The second group were patients 
who reported having had a colectomy with formation of an ileos-
tomy before the start of the study. The third group consisted of UC 
patients on infliximab or adalimumab therapy (anti-TNFα therapy).
2.3. UC-related costs
We analysed UC-related costs from a societal perspective, includ-
ing three main cost categories, as suggested by Drummond et al.,13 
outlined in Table 1. Healthcare costs were calculated by multiplying 
self-reported units of UC-related resource utilization by their unit 
prices (see Supplementary Table S1). To assess productivity losses, we 
used self-reported sick leave of employed patients from paid work. 
The number of sick leave days per week was limited to a maximum 
of 5. Hours of sick leave were valued using age- and sex-specific unit 
prices as presented in Supplementary Table S1. Patient costs, includ-
ing deductibles for healthcare insurances, over-the-counter drugs 
and travel costs, were calculated according to patient specifications. 
All costs are expressed in euros for the year 2011. Discounting was 
not applied due to the short time period considered (2 years).
2.4. Quality of life
To assess disease-specific quality of life, we used the Dutch version 
of the Inflammatory Bowel Disease Questionnaire (IBDQ).14 In addi-
tion, the EuroQol group EQ-5D-3L questionnaire was employed as a 
generic tool for quality-of-life measurement.15 The IBDQ consists of 
32 items grouped into four dimensions: bowel symptoms, systemic 
symptoms, emotional function and social function. The answers are 
rated on a graded response range from ‘worst’ (1) to ‘best’ (7) and a 
possible total score with a minimum of 32 (i.e. ‘worst’ score) to a maxi-
mum of 224 (i.e. ‘best’ score). The EQ-5D-3L consists of a descriptive 
system and comprises the following five dimensions: mobility, self-
care, usual activities, pain/discomfort and anxiety/depression. Each 
dimension has three levels: (1) no problems; (2) some problems; and 
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(3) extreme problems. EQ-5D health states, defined by the EQ-5D 
descriptive system, are converted into a weighted health state index 
(utility), the so-called quality-adjusted life year (QALY) using the 
Dutch EQ-5D tariff elicited from a Dutch general population sam-
ple.16 The QALY values obtained in this way lie on a scale on which 
full health has a value of 1 and dead a value of 0.
2.5. Ethical considerations
The study was centrally approved by the ethics committee of the 
University Medical Centre Utrecht.
2.6. Statistical analysis
Data analysis was performed using SPSS version 18.0 (Chicago, IL, 
USA). Descriptive statistics were used to characterize the three study 
groups. Means and medians were reported with a standard devia-
tion (SD) and an interquartile range (IQR), respectively. Differences 
amongst baseline characteristics were assessed by one-way ANOVA 
for continuous variables and the χ2 test for dichotomous variables. 
To account for missing data, we used a generalized mixed model to 
calculate the 3-month costs and quality of life. Despite the skewed 
nature of cost data, we reported mean costs (with 95% confidence 
intervals), as overall total costs then can be calculated. Quality-of-
life scores were presented as median and IQR.
3. Results
Figure 1 shows the study flowchart. Of the 915 UC patients included 
in the COIN study, 163 patients met the inclusion criteria, includ-
ing 81 (9%) with a pouch, 48 (5%) with an ileostomy and 34 (4%) 
on anti-TNFα therapy. In total 51/81 (63%) pouch patients, 27/48 
(56%) ileostomy patients and 25/34 (74%) patients receiving TNFα 
therapy filled out the 2-year follow-up questionnaire. The number 
of responders per 3-month intercept is provided in Supplementary 
Table S2.
Table  2 shows the baseline characteristics of the three study 
groups. Patients with an ileostomy were older than patients with a 
pouch or patients on anti-TNFα (p < 0.07). Patients on anti-TNFα 
therapy were more likely to be female compared with stoma and 
pouch patients, although this did not reach significance (p = 0.48). 
The median time since surgery was not different between pouch and 
ileostomy patients (p = 0.77). Clinical disease activity was reported 
by 35% of the patients on anti-TNFα therapy. The mean treatment 
duration of anti-TNFα therapy was 2 years in patients treated with 
infliximab and 1 year in those treated with adalimumab (p = 0.77).
3.1. UC-related healthcare use and associated costs
Table 3 presents the mean 3-month resource use within healthcare. 
Anti-TNFα patients were more likely to visit the gastroenterologist 
(p < 0.01), a specialized nurse (p < 0.01), an internist (p < 0.01) and 
a rheumatologist (p  <  0.01) compared with pouch and ileostomy 
patients. Ileostomy patients visited a specialized nurse and surgeon 
more often compared with pouch patients (p = 0.01). Colonoscopies 
and ileoscopies were more often performed in anti-TNFα-treated 
patients compared with pouch and ileostomy patients. ‘No medi-
cation use’ was encountered significantly more often in ileostomy 
patients compared with pouch patients (p  <  0.01). Ileostomy 
patients were more often hospitalized compared with patients in 
the pouch group (p < 0.01). In the anti-TNFα group, 80% received 
infliximab and 20% received adalimumab (p  < 0.01). Of all anti-
TNFα-treated patients, 42% received combination therapy with 
Table 1. UC-related cost categories and quality-of-life questionnaires used.
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Figure 1. Study flowchart.
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immunomodulators. Additional data on healthcare use is presented 
in Supplementary Tables S3–S5.
Figure 2 depicts the mean 3-monthly healthcare costs per patient. 
The mean 3-monthly healthcare costs of anti-TNFα patients were 
€5350, which was significantly higher compared with pouch and 
ileostomy patients (p  <  0.01). Medication use was the main cost 
driver, accounting for 92% of the healthcare costs. Healthcare costs 
of ileostomy patients were at least 3-fold higher compared with those 
of pouch patients (€1581 versus €407; p  <  0.01). Hospitalization 
was the main cost driver in pouch patients (50% of total healthcare 
costs), followed by medication use, accounting for 23% of healthcare 
costs. The main cost drivers in ileostomy patients were ileostomy sup-
plies (62%) and hospitalization (23%). More information regarding 
healthcare costs is presented in Supplementary Tables S3–S5.
3.2. Productivity losses and patient costs
Productivity losses due to sick leave from paid work were higher in 
anti-TNFα-treated patients than in pouch and ileostomy patients 
(€1085 versus €483 and €377; p < 0.01) Figure 3. Detailed data on 
sick leave are presented in Supplementary Table S6. Patient costs per 
3 months were €42 in pouch patients, €51 in the ileostomy group and 
€61 in the anti-TNFα group (p = 0.06). According to patient specifica-
tions, most expenditures were due to co-payments for medical costs 
not covered by healthcare insurance, vitamins and other over-the-coun-
ter drugs (e.g. anti-diarrhoeal drugs, psyllium fibre) and travel costs.
3.3. Quality of life
We found no difference between the median (IQR) IBDQ score 
in pouch, ileostomy and anti-TNFα-treated patients: 183 (156–
198), 181 (165–199) and 181 (159–199), respectively (p = 0.27). 
However, as presented in Figure 4A and Table S7A, patients with 
a pouch had lower IBDQ subscores related to bowel symptoms 
compared with patients in the ileostomy and anti-TNFα groups 
(p ≤ 0.01).
Employing the EQ-5D index, QALYs were calculated for the 
three patient groups. Pouch patients were found to have a significant 
higher median (IQR) QALY (0.90 [0.78–1.00]) compared with ile-
ostomy patients (0.84 [0.78–1.00]) and anti-TNFα-treated patients 
(0.84 [0.69–1.00]) (p  ≤ 0.01). Figure 4B and Table S7B show the 
five dimensions of the EQ-5D-3L. Patients with an ileostomy were 
found to have more mobility-related problems (p ≤ 0.01), while anti-
TNFα-treated patients had higher pain and discomfort scores com-
pared with the other groups (p ≤ 0.01).
4. Discussion
Before the introduction of anti-TNFα drugs, healthcare costs for UC 
patients who had previously undergone proctocolectomy were com-
parable with those for patients on maintenance medical therapy.17 
We expected the introduction of anti-TNFα therapy for induction 
and maintenance of remission in UC to have profoundly influenced 
the balance of healthcare costs and quality of life in these treatment 
groups.
In this unique representative cohort used to document the cost 
profiles of subgroups of UC patients, we confirmed that the average 
3-monthly healthcare costs in UC patients treated with anti-TNFα 
therapy were indeed substantively higher than in patients in whom 
a colectomy was performed. In addition, healthcare costs for ileos-
tomy patients were 3-fold higher than the costs for pouch patients, 
mainly due to hospitalization and costs of ileostomy supplies.
Table 2. Baseline characteristics of UC patients with a pouch, ileostomy versus anti-TNFα patients.
Characteristic Pouch (n = 81) Ileostomy (n = 48) Anti-TNFα (n = 34) p-value
Demographic characteristics
 Female gender (%) 36 (44.4) 21 (43.8) 19 (55.9) 0.48
 Age, years (SD) 46.7 (12.1) 53.4 (11.6) 45.4 (10.8) 0.07
 Smoking (%) 0.61
  Current 7 (8.6) 1 (2.1) 2 (5.9)
  Never 49 (60.5) 30 (62.5) 17 (50.0)
  Ex-smoker 25 (30.9) 17 (35.4) 15 (44.1)
 Weight, kg (SD) 74 (8) 75 (10) 74 (10) 0.58
 Employed (%), 18–64 years 44 (71.0) 17 (56.7) 19 (67.9) 0.39
 Disabled (%), 18–64 years
Clinical characteristics
 Disease duration (years), median (IQR) 15 (8.9) 18 (11.3) 12.6 (7.8) 0.10
 Self-reported disease activity (%) n/a n/a 12 (35.3) n/a
 Bowel complaints 14 (17.3) 6 (12.5) n/a 0.47*
 Time since surgery (years), median (IQR) 12 (3–20) 11 (2–22) n/a 0.63*
 IBDQ total, mean (SD) 187 (172–198) 181 (147–200) 177 (148–194) 0.17
 QALY, mean (SD) 0.90 (0.78–1.00) 0.84 (0.65–1.00) 0.84 (0.69–1.00) 0.38
Treatment-related characteristics
 Abdominal surgery in the past n/a n/a 2 (5.9) n/a
 Medication use in the past (%)
 Corticosteroids 69 (85.2) 41 (85.4) 29 (85.3)
 Immunomodulators 40 (49.4) 19 (39.6) 27 (79.4) <0.01
 Treatment duration
  Infliximab n/a n/a 2.0 (0.7–2.9) 0.77**
  Adalimumab n/a n/a 1.1 (0.3–1.9)
SD, standard deviation; IQR, interquartile range; IBDQ, inflammatory bowel disease questionnaire; QALY, quality-adjusted life years; n/a, not applicable.
*Pouch versus ileostomy.
**Infliximab versus adalimumab.
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The high costs for patients on anti-TNFα therapy did not come as a 
surprise. We recently reported that anti-TNFα therapy, which was pre-
scribed in just 4% of the 915 UC patients, was one of the major cost 
drivers, accounting for 31% of all healthcare costs.2 Comparison with 
previous studies is difficult, because most studies were conducted in the 
pre-biological era. For example, a recent study from Olmsted County 
showed comparable healthcare costs in medically and surgically treated 
UC patients.17 However, anti-TNF therapy was prescribed in only one 
patient and most patients were in clinical remission on conventional 
therapy, such as mesalazine and immunosuppressives. In line with our 
Table 3. Mean healthcare use per 3 months (based on all questionnaires filled out during 2 years of follow-up) in UC patients with a pouch, 
ileostomy or anti-TNFα therapy.
Pouch (n = 496) (%) Ileostomy (n = 266) (%) Anti-TNFα (n = 251) (%) p-value
Outpatient clinic
 Gastroenterologist 134 (27.0) 81 (30.5) 116 (46.2) <0.01
 Specialized nurse 53 (10.7) 77 (28.9) 92 (36.7) <0.01
 Internist 3 (0.6) 13 (4.9) 17 (6.8) <0.01
 Dietician 13 (2.6) 16 (6.0) 11 (4.4) 0.06
 Surgeon 20 (4.0) 27 (10.2) 2 (0.8) <0.01
 Rheumatologist 3 (0.6) 10 (3.8) 12 (4.8) <0.01
 Dermatologist 4 (0.8) 2 (0.8) 7 (2.8) 0.05
 Psychiatrist 2 (0.4) 3 (1.1) – 0.17
 Occupational physician 3 (0.6) 4 (1.5) 6 (2.4) 0.12
 Emergency room 14 (2.8) 14 (5.3) 4 (1.6) 0.05
 General practitioner during daytime 26 (5.2) 16 (6.0) 17 (6.8) 0.69
 General practitioner (during night/weekend) 15 (3.0) 15 (5.6) 12 (4.8) 0.19
Diagnostics procedures
 Laboratory 31 (6.2) 20 (7.5) 38 (15.1) <0.01
 Colonoscopy 11 (2.2) 7 (2.6) 28 (11.2) <0.01
 MRI scan 2 (0.4) 2 (0.8) 2 (0.8) 0.74
 CT scan 3 (0.6) 3 (1.1) – 0.25
 Abdominal X-ray 4 (0.8) 2 (0.8) 2 (0.8) 0.99
 Ultrasonography 4 (0.8) 2 (0.8) 4 1.6) 0.53
 DXA scan 7 (1.4) 3 (1.1) 4 (1.6) 0.900
Medication use
 None 302 (61.0) 148 (70.2) n/a n/a
 Adalimumab 5 (1.0) 4 (1.5) 49 (20.0) n/a
 Infliximab 3 (0.6) - 204 (80.0) n/a
 Mesalazine 24 (4.8) 34 (12.8) 144 (57.4) n/a
 Azathioprine 4 (0.8) 8 (3.0) 55 (21.9) n/a
 Mercaptopurine 4 (0.8) 1 (0.4) 37 (14.7) n/a
 Methotrexate 6 (1.2) 5 (1.9) 15 (6.0) n/a
 Corticosteroids 35 (6.2) 8 (3.0) 35 (13.9 n/a
 Antibiotics 30 (6.0) – –
Ileostomy supplies  266 (100)
Hospitalization 18 (3.6) 19 (7.1) 12 (4.8) 0.10
Surgery 7 (1.4) 3 (1.1) 1 (0.4) 0.45
CI, confidence interval; CT, computed tomography; MRI, magnetic resonance imaging; DXA, dual-emission X-ray absorptiometry; n/a, not applicable.
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Figure 2. Mean 3-monthly healthcare costs of UC patients with a pouch, ileostomy and anti-TNFα therapy.
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data, the authors of this study found that end-ileostomy was associated 
with higher healthcare costs, even without taking ileostomy supplies into 
account. Reported cumulative frequency rates of pouchitis 10–11 years 
after ileal pouch - anal anastomosis (IPAA) surgery range from 23% 
to 46%.18,19 In our study, only 17% of pouch patients reported bowel 
complaints in a window of 2 years of follow-up. Even if pouchitis was 
underrepresented in our cohort due to selection bias, this could not have 
explained the difference in costs between the two post-surgery groups.
Obviously, this observational study was not based on compara-




































































































































Figure 4. (A) IBDQ subscores in UC patients with a pouch, ileostomy and anti-TNFα therapy (median and IQR) (B) Proportion of reported problems (%) by EQ- 5D 
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Figure 3. Mean 3-monthly productivity losses and patient costs of UC patients with a pouch, ileostomy and anti-TNFα therapy.
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groups and the patients receiving anti-TNFα therapy who still had 
disease activity preclude firm conclusions regarding the long-term 
consequences of the different treatment strategies. A  randomized 
controlled trial would undoubtedly provide superior data, but will 
probably never be performed. Of note, in an earlier Olmsted County 
study a drop of almost 50% in healthcare costs was observed 2 years 
after surgery in UC patients who failed conventional therapy.20 
Obviously, a considerable decrease in healthcare costs is not antici-
pated in patients remission.
Productivity losses due to sick leave of paid work were the high-
est among patients on anti-TNFα therapy. These data should be inter-
preted with caution, given the differences in age and educational level 
between groups, with more anti-TNFα patients within the working age 
group. Evidently, disease activity played a major role in the loss of pro-
ductivity in our patients, in particular in the anti-TNF-treated group, 
as reported previously.12,21–23 Furthermore, we did not incorporate pro-
ductivity losses due to work disability, as we did not know the cause of 
work disability. However, significantly more patients in the pouch and 
ileostomy groups were work-disabled, and therefore we have probably 
underestimated the productivity losses in these groups.
We found no differences in IBQD scores between the three groups. 
There are no studies in which quality of life has been compared 
between anti-TNFα therapy versus surgery. However, our findings are 
in line with a previous study in which quality of life was compared 
between ileostomy and pouch patients using the IBDQ.24 However, 
employing the generic EQ-5D-3L, we found a difference between 
pouch and ileostomy patients. This is in contrast with previous studies 
(employing generic Short form health survey 36), in which no differ-
ence was found between pouch and ileostomy patients.25,26 It could 
be that previous studies were underpowered to detect differences in 
quality of life. Looking at the absolute QALYs in pouch (0.90) and 
ileostomy (0.84) patients, one might conclude that the overall quality 
of life in the surgery group was good.
Due to our study design, the outcome could be biased by patient 
preferences. Patients with UC occasionally decline restorative sur-
gery after subtotal colectomy for a number of reasons, such as the 
risk of decreased fecundity in young women, the risk of recurring 
pouchitis or perioperative complications, while patients with a 
pouch often put up with the disadvantages and potential complica-
tions of a pouch because an ileostomy is not acceptable to them.
The strength of our study is the uniqueness of our cost data and 
the detailed characterization of the patients and their cost profiles. Our 
findings might help to guide clinical decision-making in UC patients 
who fail conservative medical therapy and may be used for economic 
modelling. An important limitation of our study was the risk of con-
founding by indication. This is due to the fact that patients were not 
randomized for surgery or medical treatment. A randomized controlled 
trial would undoubtedly provide superior data, but will probably never 
be performed since most physicians consider pouch reconstruction the 
procedure of choice as reflected in the majority of international guide-
lines. To underscore the internal validity of our cohort, we performed 
a non-responder survey, and found no differences between responders 
and non-responders, as previously published.2
In conclusion, this is the first study aiming to provide an inte-
grated assessment of healthcare use, work absenteeism and associ-
ated costs, and quality of life in UC patients with an ileostomy or 
pouch or on anti-TNFα therapy. Despite some shortcomings, we 
were able to demonstrate that UC patients treated with anti-TNFα 
therapy had the highest healthcare expenditures. Remarkably, 
patients with an ileostomy had higher healthcare costs compared 
with patients with a pouch.
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